Clinical trials for CAR-T cell therapy for glioblastoma have shown rapid success, with patients experiencing dramatic reductions in tumor size just days after treatment. CAR-T therapy, which uses the patient’s own immune cells to fight cancer, has shown promising results in the INCIPIENT trial evaluating the safety of CARv3-TEAM-E T cells in patients with recurrent glioblastoma.
The combination of CAR-T therapy and bispecific antibodies also shows promise in preclinical models, according to results published in the New England Journal of Medicine. Patients in the trials have tolerated the infusions well, although some have experienced fevers and altered mental status as side effects.
One patient in the trial saw a 60.7% decrease in tumor size sustained for six months, while another experienced near-complete tumor regression in just five days. These early successes have researchers and oncologists optimistic about the potential to change the outlook for glioblastoma patients.
However, more research is needed to fine-tune the treatment and fully understand its long-term effects. The results of these clinical trials offer hope for a more effective and less invasive treatment option for those suffering from glioblastoma, a particularly aggressive form of brain cancer. Stay tuned to Jala News for further updates on this groundbreaking research.
